The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis
Open accessAbstract
BACKGROUND & AIMS: Eosinophilic esophagitis (EoE) is an allergen-mediated inflammatory disease with no approved treatment in the United States. Dupilumab, a VelocImmune-derived human monoclonal antibody against the interleukin (IL) 4 receptor, inhibits IL4 and IL13 signaling. Dupilumab is effective in the treatment of allergic, atopic, and type 2 diseases, so we assessed its efficacy and safety in patients with EoE. METHODS: We performed a phase 2 study of adults with active EoE (2 episodes of dysphagia/week with peak esophageal eosinophil density of 15 or more eosinophils per high-power field), from May 12, 2015, through November 9, 2016, at 14 sites. Participants were randomly assigned to groups that received weekly subcutaneous injections of dupilumab (300 mg, n = 23) or placebo (n = 24) for 12 weeks. The primary endpoint was change from baseline to week 10 in Straumann Dysphagia Instrument (SDI) patient-reported outcome (PRO) score. We also assessed histologic features of EoE (peak esophageal intraepithelial eosinophil count and EoE histologic scores), endoscopically visualized features (endoscopic reference score), esophageal distensibility, and safety. RESULTS: The mean SDI PRO score was 6.4 when the study began. In the dupilumab group, SDI PRO scores were reduced by a mean value of 3.0 at week 10 compared with a mean reduction of 1.3 in the placebo group (P = .0304). At week 12, dupilumab reduced the peak esophageal intraepithelial eosinophil count by a mean 86.8 eosinophils per high-power field (reduction of 107.1%; P < .0001 vs placebo), the EoE-histologic scoring system (HSS) severity score by 68.3% (P < .0001 vs placebo), and the endoscopic reference score by 1.6 (P = .0006 vs placebo). Dupilumab increased esophageal distensibility by 18% vs placebo (P < .0001). Higher proportions of patients in the dupilumab group developed injection-site erythema (35% vs 8% in the placebo group) and nasopharyngitis (17% vs 4% in the placebo group). CONCLUSIONS: In a phase 2 trial of patients with active EoE, dupilumab reduced dysphagia, histologic features of disease (including eosinophilic infiltration and a marker of type 2 inflammation), and abnormal endoscopic features compared with placebo. Dupilumab increased esophageal distensibility and was generally well tolerated. ClinicalTrials.gov, Number: NCT02379052.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110
Self-citationBachert, C., Mannent, L., Naclerio, R. M., Mullol, J., Ferguson, B. J., Gevaert, P., Hellings, P., Jiao, L., Wang, L., Evans, R. R., et al. (2016) · JAMA · doi:10.1001/jama.2015.19330 · Cited by 794
Self-citationCommonality of the IL-4/IL-13 pathway in atopic diseases
Gandhi, N. A., Pirozzi, G., & Graham, N. M. H. (2017) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1298443 · Cited by 493
Self-citation
Cited by
Le Floc’h, A., Allinne, J., Nagashima, K., Scott, G., Birchard, D., Asrat, S., Bai, Y., Lim, W. K., Martin, J., Huang, T., et al. (2020) · Allergy · doi:10.1111/all.14151 · Cited by 545
Self-citationDupilumab in Adults and Adolescents with Eosinophilic Esophagitis
Dellon, E. S., Rothenberg, M. E., Collins, M. H., Hirano, I., Chehade, M., Bredenoord, A. J., Lucendo, A. J., Spergel, J. M., Aceves, S., Sun, X., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2205982 · Cited by 484
Self-citationChronic Rhinosinusitis with Nasal Polyps and Asthma
Laidlaw, T. M., Mullol, J., Woessner, K. M., Amin, N., & Mannent, L. P. (2021) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2020.09.063 · Cited by 419
Self-citationEosinophils in Health and Disease: A State-of-the-Art Review
Wechsler, M. E., Munitz, A., Ackerman, S. J., Drake, M. G., Jackson, D. J., Wardlaw, A. J., Dougan, S. K., Berdnikovs, S., Schleich, F., Matucci, A., et al. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2021.04.025 · Cited by 312
Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases
Hamilton, J. D., Harel, S., Swanson, B. N., Brian, W., Chen, Z., Rice, M. S., Amin, N., Ardeleanu, M., Radin, A., Shumel, B., et al. (2021) · Clinical & Experimental Allergy · doi:10.1111/cea.13954 · Cited by 192
Self-citation
Metadata
- Authors
- Hirano, I., Dellon, E. S., Hamilton, J. D., Collins, M. H., Peterson, K., Chehade, M., Schoepfer, A. M., Safroneeva, E., Rothenberg, M. E., Falk, G. W., Assouline-Dayan, Y., Zhao, Q., Chen, Z., Swanson, B. N., Pirozzi, G., Mannent, L., Graham, N. M. H., Akinlade, B., Stahl, N., Yancopoulos, G. D., & Radin, A.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2020-01
- Volume
- 158
- Issue
- 1
- Pages
- 111-122.e10
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2978440834
- Cited by
- 460
- References
- 3
- FWCI
- 49.04
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis. https://app.cochat.ai/papers/10.1053/j.gastro.2019.09.042
- The paper
- Hirano, I., Dellon, E. S., Hamilton, J. D., Collins, M. H., Peterson, K., Chehade, M., Schoepfer, A. M., Safroneeva, E., Rothenberg, M. E., Falk, G. W., Assouline-Dayan, Y., Zhao, Q., Chen, Z., Swanson, B. N., Pirozzi, G., Mannent, L., Graham, N. M. H., Akinlade, B., Stahl, N., . . . Radin, A. (2020). Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis. Gastroenterology. https://doi.org/10.1053/j.gastro.2019.09.042
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.